New Delhi, Sept. 16 -- Recently listed Molbio Diagnostics found itself on the wrong side of a sharp reversal on Wednesday, September 16, as investors rushed to book profits following a blistering run that had seen the healthcare stock deliver strong returns in a short span.

The stock declined for the second consecutive session, falling as much as 8.8% to hit an intraday low of Rs.1,229.65 per share on the BSE. The latest decline came even as the broader Indian stock market maintained a positive trend.

Molbio Diagnostics had gained 13% in the last 1 week, defying the broader market sentiment. However, the latest sell-off has erased a significant portion of those recent gains, with the stock now down 18.5% over the last two sessions.

Mol...